AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

G2 Checkpoint Inhibitor - Pipeline Insight, 2019 by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

February 22, 2019

DUBLIN--(BUSINESS WIRE)--Feb 22, 2019--The “G2 Checkpoint Inhibitor - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

G2 Checkpoint Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across G2 Checkpoint Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

Reasons to Buy

Companies Mentioned

Topics Covered

1. Report Introduction

2. G2 Checkpoint Inhibitor - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. G2 Checkpoint Inhibitor Pipeline Products in Clinical Stages

6. G2 Checkpoint Inhibitor Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pbgkkf/g2_checkpoint?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190222005243/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/22/2019 08:01 AM/DISC: 02/22/2019 08:01 AM

http://www.businesswire.com/news/home/20190222005243/en

All contents © copyright 2019 The Associated Press. All rights reserved.